What products has 4basebio commercially released for use in research and GMP programs?

4basebio PLC is a Cambridge-based biotechnology company that develops proprietary synthetic DNA amplification technology for next-generation genetic medicines, including mRNA vaccines, viral vectors, and gene editing applications. The company's cell-free DNA manufacturing platform eliminates traditional plasmid production bottlenecks, offering faster timelines, improved safety profiles, and reduced costs compared to conventional methods. Listed on AIM, 4basebio supplies pharmaceutical partners through its opDNA® technology platform, with recent validation including FDA-approved clinical trials for mRNA therapeutics.

Sector: Telecoms
Market: AIM

Insight

What start date did 4basebio begin GMP supply and first revenue recognition under the Clinical Supply Agreement?

4basebio began GMP supply and first revenue recognition under the Clinical Supply Agreement on 20 May 2026, triggered by successful GMP batch release and delivery to the partner for the Phase II trial.

Updated 26 Aug 2026

Insight

What did 4basebio plan to present at the ASGCT Annual Meeting in Boston on 14 May 2026?

4basebio planned to present preclinical data showing its enzymatic platform can produce long-form ssDNA constructs that increase homology-directed repair efficiency while maintaining cell viability in sensitive primary cell types.

Updated 26 Aug 2026

Insight

Who is on 4basebio's Strategic Advisory Board?

4basebio's Strategic Advisory Board includes Dr Jeff Coller, who joined on 15 June 2026. He is a Bloomberg Distinguished Professor of RNA Biology and Therapeutics at Johns Hopkins and the inaugural director of the RNA Innovation Center.

Updated 26 Aug 2026

Insight

What agreement did 4basebio sign with Genezen in August 2026?

On 26 August 2026, 4basebio signed a non-exclusive Strategic Collaboration and Marketing Agreement with Genezen.

Updated 26 Aug 2026

Insight

What role does hpDNA play in 4basebio’s partnerships for clinical programme development?

4basebio uses hpDNA as starting material for drug developers’ clinical programmes via commercial enabling through partner CDMO collaboration, aiming to enable partner-led clinical programme use through Genezen’s delivery of clinical supply pathways.

Updated 26 Aug 2026

Identifiers

Ticker: AIM:4BB
Market: AIM
ISIN: GB00BMCLYF79

Learn more on:

Official site

Timeline

4basebio

4basebio signs marketing deal with viral vector CDMO Genezen

4basebio appoints Dr Jeff Coller to Strategic Advisory Board

4basebio wins opDNA supply deal for Phase II immunotherapy trial

4basebio launches enzymatic ssDNA platform

More in Telecoms

Tech Today: Optima Health revenue jumps, MTI Wireless Edge, Dotlines Global, Seeing Machines, Defence Holdings

Dotlines signs five-year Catena deal with Olilo

MTI Wireless Edge posts double-digit growth across the board

Tech Today: Anemoi secures $3.2m ahead of Trasna reverse takeover, Light Science Technologies, Ethernity Networks, Haleon, Tpximpact

Haleon prices $2bn bond to refinance 2027 notes

Ethernity flags potential upside from patent licensing push

UK authorises second oral GLP-1 pill as MedPal eyes wider funnel

Broker cuts Smith & Nephew target as pressures mount

Global Connectivity adds to working capital in management-backed equity raise

Tech Today: XP Power's order intake surges, Xaar, Focusrite, Smith+Nephew, Filtronic, Metir, MedPal AI

MedPal AI hits £8.6m revenue run rate after record July

Browse by Sector

Market reports

Energy & Resources

Financials

Technology

Healthcare

Industrials

Consumer